Amalgamated Financial’s Pyxis Oncology PYXS Stock Holding History

Amalgamated Financial’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$6K	Buy	+1,543	New	+$11.3K	﹤0.01%	2954

Other funds holding PYXS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Amalgamated Financial's PYXS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Pyxis Oncology (PYXS) in Q1 2022: 1,543 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings.

45 funds tracked by Wall St. Rank hold PYXS as of Q1 2022.

Amalgamated Financial held 1,543 shares of Pyxis Oncology worth $6K as of Q1 2022.
Pyxis Oncology was a new Amalgamated Financial position in Q1 2022.
Pyxis Oncology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2954 holding.
45 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.